Drug profile · INN
quizartinib hydrochloride
VANFLYTA
quizartinib hydrochloride (VANFLYTA) is a tyrosine-protein kinase receptor flt3 inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — quizartinib hydrochloride
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
quizartinib hydrochloride (VANFLYTA) is a tyrosine-protein kinase receptor flt3 inhibitor.
Key facts
INN quizartinib hydrochloride
Brand VANFLYTA
Mechanism Tyrosine-protein kinase receptor FLT3 inhibitor
Target Receptor-type tyrosine-protein kinase FLT3
Mechanism of action
Tyrosine-protein kinase receptor FLT3 inhibitor
Primary target: Receptor-type tyrosine-protein kinase FLT3
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is quizartinib hydrochloride?
quizartinib hydrochloride (VANFLYTA) is a tyrosine-protein kinase receptor flt3 inhibitor.
What is the brand name for quizartinib hydrochloride?
VANFLYTA is a marketed brand name for quizartinib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.